atrial fibrillation

Switching from Warfarin to Direct Oral Anticoagulants in Frail Elderly Asian Patients with Atrial Fibrillation: Insights from a Korean Nationwide Study

By MedXY 07/03/2026

In frail elderly Asian AF patients stable on warfarin, transitioning to DOACs increased risks of bleeding, thromboembolic events, and mortality, emphasizing cautious individualized management.

Cardiology news

Pulsed Field Ablation Versus Sham Procedure in Atrial Fibrillation: Insights from the PFA-SHAM Randomized Clinical Trial

By MedXY 07/01/2026

This sham-controlled trial demonstrates that pulsed field ablation significantly reduces atrial fibrillation recurrence, burden, and improves quality of life and psychological distress compared to sham treatment.

Cardiology news

Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial

By MedXY 06/10/2026

Continuous monitoring in heart failure patients revealed a high burden of arrhythmias linked to more interventions, hospitalizations, and heart failure events, but not altered by the study’s congestion-management strategy.

Cardiology Internal Medicine news

Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial

By MedXY 06/10/2026

Continuous ICM monitoring in heart failure uncovered a high arrhythmia burden, including atrial fibrillation, bradyarrhythmia, and VT/VF, which was linked to more interventions, hospitalizations, and heart failure events.

Cardiology news

Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Findings from the ALLEVIATE-HF Trial

By MedXY 06/10/2026

Continuous implantable monitoring in heart failure revealed a high burden of arrhythmias, strongly linked to hospitalizations and treatment changes, but not reduced by protocol-directed congestion management.

Cardiology news

Precardioversion Heart Rhythm Monitoring Using Smartphone Photoplethysmography: The SMARTBEATS Randomized Clinical Trial

By MedXY 06/05/2026

Smartphone photoplethysmography before planned cardioversion reduced same-day cancellations in patients with atrial fibrillation or flutter by detecting spontaneous return to sinus rhythm early.

Cardiology Diabetes & Endocrinology news

Thyroid Dysfunction Is a Cardiovascular Risk Multiplier, but Treatment Benefits Depend on Phenotype, Severity, and Age

By MedXY 06/03/2026

Thyroid dysfunction reshapes lipid metabolism, vascular tone, cardiac performance, and rhythm. Cardiovascular risk is clearest at the extremes of thyroid status, while treatment decisions in subclinical disease should remain individualized.

Cardiology Internal Medicine news

Arrhythmia Burden and Clinical Responses Under Continuous Monitoring in Heart Failure: Observations From the ALLEVIATE-HF Trial

By MedXY 06/03/2026

Continuous ICM monitoring in heart failure found a high burden of atrial fibrillation, bradyarrhythmia, and VT/VF. Arrhythmias were linked to more interventions and higher hospitalization risk, but the congestion-management strategy did not change arrhythmia occurrence.

Cardiology General Surgery news

Routine Surgical Left Atrial Appendage Occlusion Did Not Improve 1-Year Outcomes in Valvular Surgery Patients Without Atrial Fibrillation: Insights From the OPINION Trial

By MedXY 05/28/2026

In OPINION, prophylactic left atrial appendage occlusion during valve surgery did not significantly lower stroke, TIA, or cardiovascular death at 1 year in patients without pre-operative atrial fibrillation.

Cardiology Clinical Updates news

Beyond Neuronal Injury: Serum Neurofilament Light Chain as a Prognostic Biomarker for Cardiovascular Outcomes in Atrial Fibrillation

By MedXY 05/15/2026

This review analyzes the landmark SWISS-AF study, demonstrating that serum neurofilament light chain (sNfL), traditionally a marker of neuronal damage, is a potent independent predictor of major vascular events, heart failure, and mortality in patients with atrial fibrillation.

Cardiology Diabetes & Endocrinology news

Subclinical Hyperthyroidism Carries Measurable Risks of Atrial Fibrillation, Heart Failure, and Death in Primary Care

By MedXY 05/10/2026

A large Dutch primary care cohort links subclinical hyperthyroidism to higher risks of atrial fibrillation, heart failure, and all-cause mortality, with particularly notable relative risks in younger adults and in patients with more strongly suppressed TSH.

Cardiology Neurology news

Late-Life Stroke in ARIC Was More Often Embolic, and Atrial Disease Explained Much of the Risk

By MedXY 05/01/2026

In ARIC, ischemic stroke at age 80 years or older was more often embolic than thrombotic. Atrial fibrillation and left atrial disease explained much of the age effect, and adding embolic factors improved prediction.

Cardiology news

Standard-Dose DOACs Outperform Warfarin More Strongly in Asian Than Non-Asian Patients With Atrial Fibrillation

By MedXY 04/30/2026

In a patient-level meta-analysis of 10,212 Asian and 61,471 non-Asian AF patients, standard-dose DOACs outperformed warfarin more strongly in Asians, with less stroke, major bleeding, and net clinical harm. Standard-dose therapy was favored over lower-dose regimens in Asians.

Cardiology news

Pre-Treatment Fibrin Clot Lysis Time Predicts Bleeding Risk in Atrial Fibrillation Patients on Oral Anticoagulants

By MedXY 04/28/2026

Shorter pre-treatment fibrin clot lysis time independently predicts higher bleeding risk in AF patients on oral anticoagulation, as evidenced by the ARISTOTLE trial.

Cardiology Gastroenterology news

Unraveling the Gut-Heart Connection: How Leaky Gut Fuels Atrial Fibrillation in Aging

By MedXY 04/22/2026

Researchers identify JNK2 as a key mediator in gut-heart crosstalk, linking intestinal permeability to atrial fibrillation pathogenesis through inflammatory stress signals, offering new therapeutic targets.

Cardiology news

AI-Enhanced ECG Screening Pinpoints Atrial Fibrillation Risk in Older Adults: Key Insights from VITAL-AF Trial

By MedXY 04/15/2026

A VITAL-AF trial analysis reveals that combining ECG-based artificial intelligence with clinical risk scores significantly improves atrial fibrillation screening efficiency. The study demonstrates that high-risk individuals benefit most from screening, with those in the top CH-AI risk decile showing a number-needed-to-screen of just 43 per year.

Cardiology Neurology news

Timing of Atrial Fibrillation Diagnosis Does Not Alter Early Anticoagulation Benefits in Stroke Patients: Insights from the OPTIMAS Trial

By MedXY 04/05/2026

Subgroup analysis of the OPTIMAS trial reveals that neither the timing of atrial fibrillation diagnosis nor AF subtype modifies the treatment effect of early versus delayed direct oral anticoagulant initiation in acute ischemic stroke. Persistent AF, however, confers approximately double the risk of adverse outcomes compared with paroxysmal AF.

Cardiology news

Pulsed Field Ablation Matches Radiofrequency in Efficacy but Shows Superior Safety Profile for Paroxysmal Atrial Fibrillation: BEAT PAROX-AF Trial

By MedXY 04/05/2026

The BEAT PAROX-AF trial demonstrates equivalent single-procedure success rates between pulsed field ablation (77.2%) and radiofrequency ablation (77.6%) for paroxysmal atrial fibrillation, while showing a numerically lower safety event rate with PFA (3.4% vs 7.6%).

Cardiology Internal Medicine news

Memantine for Premature Atrial Contractions: A Phase 2 Randomized Clinical Trial

By MedXY 03/20/2026

This phase 2 trial demonstrates that memantine, an NMDA receptor antagonist, significantly reduces premature atrial contractions (PACs) and nonsustained atrial tachycardia burden, suggesting the cardiac glutamatergic system as a novel therapeutic target for atrial arrhythmias.

Cardiology Hematology-Oncology news

Abelacimab Shows Superior Safety Over Rivaroxaban for Older Adults with Atrial Fibrillation

By MedXY 03/12/2026

A phase 2b study demonstrates that the Factor XI inhibitor abelacimab significantly reduces bleeding risk compared to rivaroxaban in older atrial fibrillation patients, offering a safer alternative for stroke prevention in high-risk populations.